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STRUCTURED ABSTRACT 
Aims: despite optimal oral anticoagulation with vitamin K antagonist, left atrial (LA) thrombus 
could be detected in the left appendage (LAA) in more than 2% of patients with atrial fibrillation 
(AF) and CHA2DS2-VASc score ≥1 but few data are available for patients treated with non-vitamin 
K antagonist oral anticoagulants (NOACs). We evaluated the occurrence and predictors of LA 
thrombi by means of transesophageal  echocardiography (TOE) in consecutive patients with non-
valvular AF who received for at least 3 weeks Apixaban, Dabigatran, or Rivaroxaban.  
Methods: this study included 414 consecutive patients (male 252, 60.6%, mean age 67.3 years) 
referred to our Centers for catheter ablation of AF (n=220, 53.1%) or scheduled electrical 
cardioversion (n=194, 46.9%). Patients were on Dabigatran (n=160), Rivaroxaban (n=150) or 
Apixaban (n=104). TOE was performed in all cases within 12 hours prior to ablation or 
cardioversion. 
Results: preprocedural TOE revealed LA thrombus in 15/414 patients (3.6%), all located in the 
LAA (Apixaban 3/104 2.9%, Dabigatran 5/160 3.1%, and Rivaroxaban 7/150 4.7%, p=0.69). Of 
these, 14 patients had persistent AF. Patients with LAA thrombus had a mean CHA2DS2-VASc 
score of 3 (3-4). Higher CHA2DS2-VASc score (p=0.02), but not the type of NOAC, significantly 
predicted the presence of LA thrombus. 
Conclusion: the incidence of LAA thrombus in a cohort of patients anticoagulated with NOACs is 
low but not negligible, in any case similar among the 3 drugs.  Preprocedural TOE should be 
considered in patients with a CHA2DS2-VASc score > 3. 
KEY-WORDS: atrial fibrillation; non-vitamin K antagonist oral anticoagulants; left atrial thrombus; 
transesophageal  echocardiography.  
1. INTRODUCTION 
Atrial fibrillation (AF) is the most frequently sustained cardiac arrhythmia, with a prevalence of 
about 2-3% in the general population.(1) Cardioversion (both electric and pharmacological) in 
patients with AF is associated with a risk of systemic embolism ranging from 5% to 7% without 
adequate anticoagulation.(2) Vitamin K antagonist therapy significantly reduced the risk of 
thromboembolic events (0.7% to 0.8%).(3) For patients with AF of > 48 hours duration, current 
Guidelines recommend adequate anticoagulation for at least 3 weeks before and 4 weeks after 
cardioversion(1). However, previous studies suggest that the incidence of left atrial (LA)/LA 
appendage (LAA) thrombus under treatment with vitamin K antagonist (VKAs) ranges between 0.6 
and 7%.(4-6) 
Novel oral anticoagulants (NOACs) are alternatives to vitamin K antagonist therapy for long-term 
stroke prevention in patients with non-valvular AF.(7-10) However, there are still underexplored 
aspects related to the management of patients on NOACs. Specifically, estimates of the prevalence 
of LA/LAA thrombus after adequate anticoagulation with NOAC are mainly based on randomized 
trials whereas “real life” data are lacking.(11-14) Transesophageal echocardiogram (TOE) is a 
moderately invasive method that allows a detailed evaluation of the structure and function of the 
LAA. It is accurate and the gold standard for identifying or excluding LA/LAA thrombus.(15) 
Therefore, we designed this study to assess prevalence and predictors of LAA thrombus at TOE 
performed before elective electrical cardioversion or catheter ablation for AF in patients treated 
with different NOACs. 
 
2. METHODS 
2.1 Setting. This multicenter study enrolled consecutive patients (18 years or older) with a 
CHA2DS2-VASc score > 1, who underwent TOE before scheduled electrical cardioversion or 
ablation for AF at 6 Italian Centers (University Hospital, Padova; Clinica Mediterranea, Napoli; 
University Hospital, Torino; Ospedale Monaldi, Napoli; Federico II University Hospital, Napoli; 
Pellegrini Hospital, Napoli) from January 2015 to May 2016 on NOAC therapy with Apixaban, 
Dabigatran, or Rivaroxaban (Edoxaban was not commercially available in Italy at the time of the 
study).  
Exclusion criteria were AF due to a reversible cause (e.g., hyperthyroidism, infection, transient 
perioperative AF), moderate or severe mitral valve stenosis, mechanical heart valve, heart 
transplant, need for aspirin at a dose of >100 mg/day or dual antiplatelet therapy, active liver 
disease, calculated creatinine clearance of <30 ml per minute, pregnancy, stroke within 14  days, 
LA thrombus documentation within 3 months, off-label drug dosages and non-compliance with 
drug therapy.  
This retrospective observational study was approved by our institutional review committees, and all 
subjects gave written informed consent. 
2.2 Clinical evaluation. Type of AF (paroxysmal or persistent, according to definition of 2016 ESC 
Guidelines),(1) medical background of patient (in particular the presence of structurally heart 
disease or coronary artery disease), and CHA2DS2-VASc score of all subjects were evaluated. 
2.3 Management of anticoagulation therapy. All study patients were anticoagulated with 
Apixaban, Dabigatran, or Rivaroxaban for at least 3 weeks and performed TOE within 12 hours 
from the last intake of the drug. Patients scheduled for catheter ablation withdrawn Apixaban and 
Dabigatran 12 hours, and Rivaroxaban 24 hours before ablation. 
2.4 Echocardiographic evaluation. All included patients were studied by transthoracic and 
transoesophageal (TOE) echocardiogram (Vivid E9, GE HVingmed, Horten, NO; iE33 xMATRIX, 
Philips, Andover, MA, USA)). Echocardiographic measurements were performed according to the 
current recommendations.(16) Transthoracic echocardiogram was performed on the day before or 
on the same day of the procedure using a 1.5–4.6 MHz (M5S-D and M5Sc-D, GE Vingmed) or a 
1.0-5.0 MHz (S5-1, Philips) imaging transducer. 
TOE was performed within 12 hours prior to catheter ablation or just before electrical 
cardioversion. Blood pressure, heart rate, and oxygen saturation were continuously monitored. A 
3.0–8.0 MHz multiplane phased array transducer (6VT-D, GE Vingmed; or X7-2T, Philips) was 
used. In particular, cine loops of the LA appendage were obtained during stepwise rotation of the 
imaging sector in 5-10 degree increments from 0 to 180 degrees during continuous visualization of 
the LA appendage. LA thrombus was defined as an echodense intracavitary mass distinct from the 
underlying endocardium and not caused by pectinate muscles.(17)  
2.5 Statistical analysis. Data are expressed as mean±SD or median with 25 to 75 percentiles for 
normally distributed and skewed variables, respectively. Normality was assessed with the Shapiro-
Wilk test. To assess differences among the 3 groups, categorical variables were compared with the 
2 test while continuous variables were compared with the Kruskall-Wallis Test. Post-hoc 
comparisons between 2 groups were performed using the Bonferroni correction. A value of P < 
0..05 was considered significant. Because of the small number of events multivariate analysis was 
not performed. Statistics were analyzed with SPSS version 19 ( SPSS, Inc, Chicago, IL). 
 
3. RESULTS 
3.1 Clinical data. Data from 414 consecutive patients on NOAC referred for AF catheter ablation 
(n=220 53,1%) or scheduled electrical cardioversion (n=194, 46.9%) were collected. All patients 
were anticoagulated with NOAC: Apixaban (n=104, 25.1%), Dabigatran (n=160, 38.7%), and 
Rivaroxaban (n=150, 36.2%). A low NOAC dose of was taken by 18 (4.3%) patients. Clinical data 
are shown in Table 1. 
3.2 Echocardiographic data. Echocardiographic data are shown in Table 1. The mean LA volume 
resulted of 80.9 ml. At TOE, a thrombus was present in 15 patients (3.6%), always located in the 
LAA. 
3.3 Characteristics of patients with thrombus at TOE. Patients with LAA thrombus had a mean 
CHA2DS2-VASc score of 3 (3-4), a mean LA volume of 78 ml (39-148 ml), and 14/15 patients had 
persistent AF. Only 1 patient  took a low NOAC dose (Dabigatran 220 mg  daily).  
Patients with LAA thrombus showed a significantly higher CHA2DS2-VASc score than patients 
without (p=0.02) (Table 2). In particular, a CHA2DS2-VASc score > 3 was present in 6 patients. 
Among variables of CHA2DS2-VASc score, only history of heart failure, diabetes, and previous 
stroke/TIA predicted the presence of LAA thrombus. 
3.4 Comparison among NOACs. Clinical and echocardiographic characteristics of patients on 
Apixaban, Dabigatran, and Rivaroxaban were similar (Table 3). A LAA thrombus was found in 
3/104 (2.9%) patients on Apixaban, 5/160 (3.1%) patients on Dabigatran, and 7/150 (4.7%) patients 
on Rivaroxaban (p=0.69). 
3.5 Thromboembolic complications and management of patients with LAA thrombus. Among 
the 399 patients without LAA thrombus at TOE we did not observe any embolic complication 
during or after electrical cardioversion or catheter ablation. In the 15 patients with LAA thrombus 
the scheduled procedure was not performed, NOAC was substituted with full dose enoxaparin (100 
UI per kg bid) imbricated with warfarin, with the aim to maintain an INR between 2.5 and 3.5. 
After 4 to 8 weeks of anticoagulation with warfarin the thrombus disappeared and the scheduled 
procedure was performed in all but one patients. We did not observe embolic complications in any 
of these 15 patients. 
 
4. DISCUSSION    
4.1 Main findings. 1) In a cohort of patients anticoagulated with NOACs the incidence of LAA 
thrombus was low but not negligible. 2) The incidence of LAA thrombus appeared similar among 
patients treated with Apixaban, Dabigatran, and Rivaroxaban. 3) Preprocedural TOE should be 
considered in patients with a CHA2DS2-VASc score > 3.  
4.2 Incidence of LA thrombus on anticoagulation therapy. Systemic and cerebral 
thromboembolism is one of the most feared complications of AF. In patients scheduled for elective 
cardioversion for AF >48 hours of duration current Guidelines recommend a sufficient therapeutic 
anticoagulation least 3  weeks before the procedure.(1) 
 Previous studies in patients treated with VKAs reported an incidence of systemic embolism 
in anticoagulated patients undergoing elective cardioversion of about 1%. In the RE-LY trial 
(Dabigatran vs. VKAs), a cardioversion was performed in 1270 patients. Stroke or systemic 
embolism at 30  days after cardioversion occurred in 0.8%, 0.3%, and 0.6% of patients receiving 
Dabigatran 220mg daily, Dabigatran 300mg daily, and VKAs, respectively.(7) In the ROCKET-AF 
trial (Rivaroxaban vs. VKAs ), cardioversion or catheter ablation was carried out only in 364 
patients. The occurrence of stroke or systemic embolism was reported only at the end of the follow-
up, and resulted respectively of 1.88 % and 1.86% in patients receiving Rivaroxaban and VKAs.(8) 
Two recent studies specifically address NOAC for cardioversion. In the X-VeRT trial 1504 patients 
receiving cardioversion were randomized to VKAs or Rivaroxaban. Stroke or systemic embolism at 
30  days after cardioversion occurred in 1.02% of patients on VKAs and in 0.51% of patients on 
Rivaroxaban.(14) More recently, ENSURE-AF trial randomized 2199 patients waiting for 
cardioversion to VKAs or Edoxaban. The primary efficacy composite endpoint of stroke, systemic 
embolic event, myocardial infarction, and cardiovascular mortality occurred in 1.0% of patients of 
both arms.(18)   
 The results of the above-mentioned studies suggest that the risk of systemic embolism in 
elective cardioversion is not negligible and this may be the result of persistent LA/LAA thrombus 
despite adequate anticoagulation. TOE is a moderately invasive method that allows a detailed 
evaluation of the structure and function of the LAA. It is accurate and the gold standard for 
identifying or excluding LA/LAA thrombus.) The incidence of LAA thrombus under treatment with 
VKAs depends on the patient population studied and on the time on therapeutic range: however, in 
most studies on patients treated with VKA the incidence of LAA thrombus was between 0.6 and 
7 %.(4-7,9,14,19) In the present study of real world, we observed a 3,6% incidence of LAA 
thrombus among 414 patients treated with NOAC, a figure which is similar to previous studies in 
patients with VKAs. 
4.3 Comparison among NOACs. According to our study, LAA thrombus occurred in 2.9% of 
patients on Apixaban, in 3.1% of patients on Dabigatran, and in 4.7% of patients on Rivaroxaban. 
In the Literature, most of the data about the rate of LAA thrombus in patients on NOACs comes 
from Dabigatran and Rivaroxaban. Including our data (Figure 1), 751 patients on Dabigatran 
220 mg or 300 mg daily,(11, 20-22)  608 patients on Rivaroxaban 15 or 20 mg daily,(14, 20-22) 
and 280 patients on Apixaban 5 or 10 mg daily (13, 22) were evaluated with TOE after at least 3 
weeks of anticoagulation. The incidence of LAA thrombus was similar between Apixaban (3/280, 
1.1%) and Dabigatran (11/751, 1.4%), while slightly higher for Rivaroxaban (19/608, 3.1%). This 
result was mainly due to the very high occurrence of LAA thrombi (18.2%) in the 33 patients 
enrolled in the X-VeRT trial who underwent TOE before elective cardioversion.(14) Of note, only 
≈10% of patients scheduled for elective cardioversion in the X-vert trial underwent TOE but the 
reasons for the choice were not provided: lack of adherence in taking Rivaroxaban might be one, 
and this could have reduced the anticoagulant effect of Rivaroxaban. 
4.4 Predictors of LAA thrombus. Our results support previous work showing that the CHADS2 
and CHA2DS2-VASc scores predict the presence of LAA thrombus in patients before AF ablation. 
(4,5,21-22) In particular, history of heart failure, diabetes, and previous stroke/TIA identified 
patients with LAA thrombus. CHADS2 and CHA2DS2-VASc score demonstrated to be useful for 
predicting thromboembolic events and mortality after catheter ablation for AF.(6,23) So, it is not 
surprising that patients with a very high risk score for thromboembolism could be refractory to 
standard anticoagulation. 
On the contrary, we did not confirm the role of LA dimension as predictor of LAA thrombus 
(4,5,21). This discrepancy could be explained by the different method of measuring LA size: LA 
diameter in previous studies, LA volume in our study. 
 5. STUDY LIMITATIONS.  
The study had a retrospective, non randomized design. The relatively small number of patients 
investigated in this study impeded to perform a comparison among NOACs with a statistically 
significant power. Logistic regression was not calculated for individual comparisons owing to the 
low event rate.  We enrolled a selected cohort of AF patients, that undergo rhythm control strategy. 
Therefore, our results cannot be extrapolated to all AF patients. Further studies should address the 
present issues in a larger patient cohort including Edoxaban patients. 
We have not clear explanations of the effect of warfarin on LAA thrombi. The simplest 
interpretations of this phenomenon are: 1) warfarin has a stronger anticoagulant power than NOACs 
when a high INR level is maintained; 2) thrombi, we do not know if they were already present when 
NOAC started, sometime need more time to dissolve. 
 
6. CONCLUSIONS.  
The incidence of LAA thrombus in a cohort of patients anticoagulated with NOACs is low but not 
negligible, in any case similar among Apixaban, Dabigatran, and Rivaroxaban. Patients with a 
CHA2DS2-VASc score > 3 showed a higher chance of LAA thrombus suggesting that preprocedural 
TOE should be considered in these individuals. 
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TABLES 
Table 1:  Clinical and echocardiographic characteristics of the 414 study patients. 
 
 
 
 
 
 
 
 
 
 
 
 
Data are presented as mean (SD), unless otherwise indicated. AF=atrial fibrillation; 
TOE=transesophageal echocardiogram.
Male gender  (%) 252 (61%) 
Age (years) 67±1.2 
Arterial hypertension (%) 218 (53%) 
Coronary artery disease 73 (18%) 
Left atrial volume (ml) 80,9 
Congestive heart failure (%) 11 (2,6%) 
Vascular disease (%) 81 (19,6%) 
Paroxysmal AF   (%) 53 (13%) 
Diabetes (%) 69 (16,7%) 
Previous stroke/TIA (%) 30 (7,2%) 
CHA2DS2-VASc score 2.6±1.2 
AF at TOE (%) 239 (57,7%) 
Thrombus at TOE (%) 15 (3,6%) 
Table 2:  Univariate analysis for comparisons between patients with and without LAA thrombus 
at TOE. 
 No Thrombus 
N=399 
Thrombus 
N=15 
p 
Mean age 68 (60-74) 73 (62-73) 0.72 
Males 239 (60%) 12 (80%) 0.18 
CHA2DS2VASc 2 (2-3) 3 (3-4) 0.013 
CHA2DS2VASc>3 88 (22%) 7 (47%) 0.026 
Arterial Hypertension (%) 261 (66%) 6 (40%) 0.07 
Coronary artery disease 73 (18%) 4 (27%) 0.50 
LA volume (ml) 75 (57-103) 78 (39-148) 0.72 
Congestive heart failure (%) 7 (1,7%) 4 (26,6%) 0,001 
Vascular disease (%) 77 (19,4%) 4 (26,7%) 0,50 
Diabetes (%) 63 (15,9%) 6 (40%) 0,014 
Previous stroke/TIA (%) 26 (6,6%) 4 (26,7%) 0,03 
Paroxysmal AF 52 (13%) 1 (6.7%) 0.70 
Type of NOAC 
Dabigatran 
Rivaroxaban 
Apixban 
 
154 (39%) 
143 (36%) 
101 (25%) 
 
5 (3.1%) 
7 (4.7%) 
3 (2.9%) 
 
0.69 
Low NOAC dose 17 (4%) 1 (7%) 0.49 
Data are presented as mean (SD), unless otherwise indicated. 
AF=atrial fibrillation; TOE=transoesophageal echocardiogram
Table 3:  Clinical and echocardiographic characteristics of patients on Apixaban, Dabigatran, and Rivaroxaban. 
Data are presented as mean (SD), unless otherwise indicated. AF=atrial fibrillation;  TOE=transesophageal echocardiogram. 
     Among groups Post-Hoc (Bonferroni) 
 Overall 
N=414 
Dabigatran 
N=160 
Rivaroxaban 
N=150 
Apixaban 
N=104 
p p                   
(D vs R) 
p                  
(D vs A) 
p             
(R vs A) 
Mean age (years) 67±1.2 66.7±9.8 67.2±10.6 68.3±9.5 0.49    
Males 252 (61%) 97 (61%) 86 (57%) 69 (66%) 0.34    
CHA2DS2VASc 2.6±1.2 2.4±1.2 2.7±1.3 2.8±1.2 0.04 0.30 0.04 0.34 
CHA2DS2VASc>3 95 (23%) 30 (19%) 42 (28%) 23 (22%) 0.15    
Arterial Hypertension (%) 218 (53%) 54 (34%) 95 (63%) 69 (66%) 0.90    
Coronary artery disease (%) 77 (19%) 25 (16%) 27 (18%) 25 (24%) 0.24    
Left atrial volume (ml) 80,9 85±39 80±32 76±30 0.16    
Congestive heart failure (%) 11 (2,6%) 5 (3,1%) 2 (1,3%) 4 (3,8%) 0,23    
Vascular disease (%) 81 (19,6%) 26 (16,5%) 29 (19,5%) 26 (25%) 0,23    
Diabetes (%) 69 (16,7%) 27 (17,1%) 25 (16,8%) 17 (16,3%) 0,9    
Previous stroke/TIA (%) 30 (7,2%) 9 (5,7%) 9 (6,0%) 12 (11,5%) 0,16    
Paroxysmal AF (%) 53 (13%) 30 (19%) 12 (8%) 11 (7%) 0.01 0.015 0.21 1.0 
Low NOAC dose 18 (4.3%) 14 (9%) 4 (3%) 0 <0.001 0.06 0.002 0.30 
LAA Thrombus 15 (3.6%) 5 (3.1%) 7 (4.7%) 3 (2.9%) 0.69    
FIGURE LEGEND 
Figure 1: LAA thrombus in patients on Dabigatran, Rivaroxaban, and Apixaban in the 
Literature. 
 
 
 
